

# Parkinson's Disease



# LRRK2 G2019S tg Rat Model


This Parkinson's disease rat model is transgenic for the human LRRK2 G2019S gene. Rats are used heterozygous.

- · Increased total LRRK2 levels
- Increased pS935 LRRK2 levels
- Unchanged pS1292 LRRK2 levels
- Phosphorylation status modifiable by LRRK2 inhibitor MLi-2


iPSCs with LRRK2 mutation can be used for in vitro analyses

Figure 1:
Time-dependent inhibition
of LRRK2 kinase activity
upon single oral MLi-2
treatment. LRRK2 G2019S
tg rats received a single
dose of MLi-2 or vehicle
and were sacrificed 2, 8, or
24 hours later. Brain levels
of total LRRK2 (A), pS935
LRRK2 (B), and pS1292
LRRK2 (C) were quantified
by immunosorbent assay.
Mean ± SEM; n = 3-4 per
group. Two-way ANOVA
with Bonferroni's post hoc
test; "p<0.01, ""p<0.001;
ns, not significant.


# Figure 1 Total LRRK2 Levels



## pS935 LRRK2 Levels



# pS1292 LRRK2 Levels



Discovery

## Important note

Representative data are shown throughout this document. However, biological variability might cause deviations from shown data.

## Scantox Group, HQ

Hestehavevej 36A, Ejby DK – 4623 Lille Skensved clientservice@scantox.com www.scantox.com +45 5686 1500

## © Scantox A/S

Scantox is a registered trademark of Scantox A/S.

